Advertisement
CANF vs GNPX
Which Stock Would AI Choose? Can-Fite BioPharma (CANF) vs. Genprex (GNPX) Stock Comparison
Key Takeaways
- Both CANF and GNPX are clinical-stage biotechnology micro-caps, meaning their share prices are driven primarily by clinical data, regulatory milestones, and financing events rather than revenue or earnings.
- CANF is advancing two late-stage (Phase III) drug candidates and has recently reported encouraging survival data, while GNPX remains earlier in development and has leaned on patent and biomarker announcements to drive sentiment.
- Both stocks have experienced sharp drawdowns over the past year, with GNPX showing materially higher volatility and a history of reverse stock splits and share dilution that has weighed on its market positioning.
- Tickeron AI Verdict: Based on trend consistency, pipeline maturity, financing stability, and relative volatility, the AI would currently favor CANF over GNPX.
- For deeper coverage, explore CANF Major News and CANF Today's Price Move, as well as GNPX Major News and GNPX Today's Price Move.
- To see which strategies are currently outperforming across the market, browse the curated Trending AI Robots.
Introduction
Investors comparing CANF and GNPX are looking at two small-cap biotechnology companies whose fortunes hinge on the outcomes of clinical trials and their ability to raise capital. This stock comparison is most relevant to traders and investors who follow event-driven, high-volatility healthcare names and want to understand how pipeline maturity, financing activity, and market positioning differ between two companies operating in overlapping oncology territory. While neither company is profitable, their recent news flow, cash positions, and technical profiles tell very different stories about stability and near-term risk. Understanding these contrasts can help readers evaluate relative performance without relying on single-day price moves.
CANF Overview and Recent Performance
CANF is Can-Fite BioPharma Ltd., an Israel-based, clinical-stage biopharmaceutical company developing oral, small-molecule drugs that target the A3 adenosine receptor for cancer, liver, and inflammatory diseases. Its lead candidates are Piclidenoson and Namodenoson, both of which are advancing in late-stage trials. In recent weeks, the company has reported longer-than-anticipated overall survival in its ongoing pivotal Phase III liver cancer study, presented final Phase IIa pancreatic cancer data at the ESMO 2026 conference, and completed enrollment for an interim analysis of its pivotal Phase III psoriasis study for Piclidenoson.
Despite this steady flow of clinical news, CANF shares have trended lower in recent market activity, trading near the lower end of a 52-week range that reflects a steep year-over-year decline. Sentiment has been pressured by equity financing, including a roughly $4 million warrant exercise, and by the dilution concerns typical of pre-revenue biotechs. Analyst coverage remains generally constructive, with at least one firm maintaining a Buy rating and price targets well above recent levels, though these targets reflect long-term clinical optionality rather than near-term fundamentals.
GNPX Overview and Recent Performance
GNPX is Genprex, Inc., a clinical-stage gene therapy company based in Austin, Texas, developing therapies for cancer and diabetes. Its lead oncology candidate, Reqorsa (a TUSC2 gene therapy delivered via the Oncoprex nanoparticle system), is being studied in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), while its GPX-002 program targets diabetes. Recent announcements have centered on intellectual property, including patent grants and allowances in multiple jurisdictions, and on biomarker research identifying TROP2 and PTEN as potential predictors of treatment response, including a collaboration with Roche Diagnostics.
GNPX has shown pronounced volatility in recent market activity, with sharp spikes on patent and regulatory headlines followed by sustained declines. Over the past year, the stock has fallen sharply from its highs, and its profile has been complicated by multiple reverse stock splits and recurring share issuance, which have diluted existing holders and eroded market confidence. With a market capitalization well under $10 million and limited cash runway, financing and continued-listing considerations remain central risks for the company.
Trending AI Robots
For investors who prefer a systematic approach to navigating volatile names like CANF and GNPX, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts a large library of AI Trading Bots that collectively trade thousands of different tickers, yet only a select group earns a place in this section based on their current fit with market conditions. These bots span a wide range of trading styles, timeframes, strategies, performance metrics, and ticker universes, allowing users to compare approaches rather than rely on a single model. Browsing the page can help traders identify data-driven signals and refine their own market positioning.
Head-to-Head Comparison
Although both companies operate in the oncology space, their risk profiles diverge meaningfully. CANF is further along clinically, with two Phase III programs, a diversified pipeline spanning cancer, liver, inflammatory, and metabolic indications, and recent cash infusions that extend its runway. Its catalysts are relatively broad and data-driven. In contrast, GNPX is more heavily concentrated in early- and mid-stage gene therapy programs, with much of its recent momentum tied to patent and biomarker news rather than late-stage efficacy data. Its financing history, including repeated reverse splits, introduces structural risks that CANF has not faced to the same degree. On volatility, GNPX has traded with wider swings and a deeper drawdown, while CANF, though also down substantially, has shown a steadier, less extreme technical profile and retains formal analyst coverage with price targets.
Tickeron AI Verdict
Weighing observable factors such as pipeline maturity, trend consistency, financing stability, and relative volatility, Tickeron's AI would likely favor CANF over GNPX in the current environment. CANF offers more advanced clinical programs, a steadier catalyst calendar, and a less diluted capital structure, all of which tend to support a comparatively more stable market positioning. GNPX, by contrast, carries higher structural and financing risk that could continue to weigh on its relative performance despite occasional headline-driven rallies. This assessment reflects probabilistic, model-based reasoning rather than a prediction of future prices.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and GNPX is a Hold.
CANF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CANF turned positive on November 02, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, 35 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 71 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on CANF as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 153 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CANF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.715) is normal, around the industry mean (3.498). P/E Ratio (-0.349) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GNPX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GNPX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 32 similar instances where the indicator exited the overbought zone. In 32 of the 32 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Oscillator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on GNPX as a result. In 60 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CANF | GNPX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 93 | |
P/E GROWTH RATING 1..100 | 9 | 84 | |
SEASONALITY SCORE 1..100 | n/a | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (49) in the Pharmaceuticals Major industry is in the same range as CANF (54) in the Biotechnology industry. This means that GNPX’s stock grew similarly to CANF’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CANF (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to CANF’s over the last 12 months.
GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CANF (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to CANF’s over the last 12 months.
CANF's Price Growth Rating (86) in the Biotechnology industry is in the same range as GNPX (93) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to GNPX’s over the last 12 months.
CANF's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for GNPX (84) in the Pharmaceuticals Major industry. This means that CANF’s stock grew significantly faster than GNPX’s over the last 12 months.
| CANF | GNPX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 79% | N/A |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 77% | 13 days ago 76% |
| Declines ODDS (%) | 16 days ago 87% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CANF’s FA Score shows that 1 FA rating(s) are green while GNPX’s FA Score has 0 green FA rating(s).
- CANF’s FA Score: 1 green, 4 red.
- GNPX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CANF’s TA Score shows that 6 TA indicator(s) are bullish while GNPX’s TA Score has 4 bullish TA indicator(s).
- CANF’s TA Score: 6 bullish, 2 bearish.
- GNPX’s TA Score: 4 bullish, 3 bearish.
Price Growth
CANF (@Biotechnology) experienced а +2.47% price change this week, while GNPX (@Biotechnology) price change was -9.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
GNPX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -1.19% | ||
| GNPX - CANF | 93% Closely correlated | +1.46% | ||
| ICU - CANF | 91% Closely correlated | -3.06% | ||
| MLEC - CANF | 89% Closely correlated | N/A | ||
| LONA - CANF | 78% Closely correlated | -10.07% | ||
| NCEL - CANF | 62% Loosely correlated | +4.00% | ||
More | ||||
GNPX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | +1.46% | ||
| CANF - GNPX | 93% Closely correlated | -1.19% | ||
| APVO - GNPX | 86% Closely correlated | -4.42% | ||
| ICU - GNPX | 82% Closely correlated | -3.06% | ||
| MLEC - GNPX | 76% Closely correlated | N/A | ||
| LONA - GNPX | 76% Closely correlated | -10.07% | ||
More | ||||